Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506328 | 0.80 | HSD17B10 (0.43) | HSD17B10KDM4EALDH1A1HRH4HRH3 | |
| SCHEMBL17674371 | 0.80 | HSD17B10 (0.43) | HSD17B10KDM4EALDH1A1HRH4HRH3 | |
| SCHEMBL30791898 | 0.79 | HSD17B10 (0.42) | HSD17B10KDM4EALDH1A1DYRK1APDE1B | |
| SCHEMBL26621529 | 0.79 | HSD17B10 (0.42) | HSD17B10KDM4EALDH1A1DYRK1APDE1B | |
| SCHEMBL30385415 | 0.79 | HTT (0.42) | HSD17B10KDM4EALDH1A1DYRK1APDE1B | |
| SCHEMBL20741029 | 0.79 | HSD17B10 (0.42) | HSD17B10KDM4EALDH1A1DYRK1APDE1B | |
| SCHEMBL27259688 | 0.78 | KDM4E (0.43) | HSD17B10KDM4EALDH1A1DYRK1AHTT | |
| SCHEMBL30224197 | 0.72 | GRIN1 (0.35) | HSD17B10 | |
| SCHEMBL33526579 | 0.72 | HRH4 (0.35) | KDM4EALDH1A1HRH4 | |
| SCHEMBL33526125 | 0.71 | ALOX15 (0.31) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | HSD17B10 1101/4885KDM4E 2674/4885ALDH1A1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.